伴骨髓增生异常相关改变的急性髓系白血病结局取决于诊断标准与治疗
该研究纳入2013至2018年治疗的415例AML-MRC患者,依据诊断标准、治疗类型和突变谱分析结局。多因素分析显示AML-MRC亚型、年龄和血清LDH是独立预后因素,AML-MRC-M和AML-MRC-H总生存较好,强化治疗可改善部分亚组生存。
要点
- AML-MRC不同诊断标准定义的患者预后异质,并非均为高危。
- AML-MRC-M和AML-MRC-H的生存与中危AML相似。
- 强化治疗可改善AML-MRC-M和AML-MRC-H的生存结局。
核心结论
- 并非所有AML-MRC诊断标准都定义高危患者,特定亚组可能从不同治疗干预中获益。
研究设计与样本
- 回顾性分析415例2013至2018年治疗的AML-MRC患者,基于诊断标准、治疗类型和突变谱评估结局。
主要发现
- AML-MRC-C占243例(59%),AML-MRC-H占47例(11%),AML-MRC-TS占28例(7%),AML-MRC-M占97例(23%)。
- 中位年龄70岁(范围18-94)。
- 95例可评估患者中37例(39%)具有继发性型突变(ASXL1、BCOR、EZH2、SF3B1、SRSF2、STAG2、U2AF1、ZRSR2)。
- 与468例无MRC的AML队列相比,AML-MRC-M/AML-MRC-H的结局与欧洲白血病网标准的中危AML相似。
临床怎么用
- 临床应识别AML-MRC亚型,AML-MRC-M和AML-MRC-H可能从强化治疗中获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) is a heterogeneous disorder defined by multilineage dysplasia, myelodysplastic syndrome (MDS)-related karyotype, or history of prior MDS. We evaluated 415 patients with AML-MRC treated from 2013 to 2018 and analyzed their clinical outcomes based on the diagnostic criteria of AML-MRC, therapy type and mutation profile. Criteria for AML-MRC included: cytogenetic abnormalities (AML-MRC-C) in 243 (59%), prior history of MDS in 75 (18%) including 47 (11%) with previously untreated MDS (AML-MRC-H) and 28 (7%) with previously treated MDS (AML-MRC-TS), and 97 (23%) with multilineage dysplasia (AML-MRC-M). Median age was 70 years (range 18-94). Among 95 evaluable patients, a total of 37 (39%) had secondary-type (ASXL1, BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, ZRSR2) mutations. Mutations in ASXL1, BCOR, SF3B1, SRSF2, and U2AF1 tended to appear in dominant clones. By multivariate analysis, AML-MRC subtype, age and serum LDH levels were independent predictors of outcome, with patients with AML-MRC-M (HR 0.56, CI 0.38-0.84, P = .004) and AML-MRC-H having better OS. Compared to a cohort of 468 patients with AML without MRC, patients with AML-MRC-M/AML-MRC-H had similar outcomes to those with intermediate risk AML by European LeukemiaNet criteria. Intensive therapy was associated with improved OS in patients with AML-MRC-M (HR 0.42, CI 0.19-0.94, P = .036) and with improved EFS in AML-MRC-M and AML-MRC-H (HR 0.26, CI 0.10-0.63, P = .003). This data suggests that not all diagnostic criteria for AML-MRC define high-risk patients and that specific subgroups may benefit from different therapeutic interventions.
引用
- Montalban-Bravo G, Kanagal-Shamanna R, Class CA, et al. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020. PMID: 32112433. doi:10.1002/ajh.25769
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。